By Fineline Cube Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China’s National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).
Regulatory & Development Milestone
| Item | Detail |
|---|---|
| Company | Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) |
| Drug | Firsekibart (IL-1β monoclonal antibody) |
| Regulatory Agency | NMPA (China) |
| Approval Type | Clinical trial authorization |
| Indication | Prevention of acute gout flares during initial ULT phase |
| Drug Classification | Category 1 innovative drug |
| Previous Approval | July 2025 for acute gouty arthritis attacks |
Drug Profile & Clinical Strategy
Current Approved Indication
Firsekibart, an IL-1β monoclonal antibody (mAb), was initially approved in July 2025 in China for:
- Adult patients with acute gouty arthritis attacks
- Patients contraindicated for, intolerant of, or unresponsive to NSAIDs and/or colchicine
- Patients unsuitable for repeated corticosteroid use
New Clinical Development Pathway
The newly approved clinical study aims to expand firsekibart’s utility into prophylactic use during the critical initial phase of urate-lowering therapy, where up to 70% of patients experience acute flares due to rapid changes in serum uric acid levels.
Market Access & Reimbursement Outlook
- NRDL Inclusion: Firsekibart has been included in the pre-communication list for 2026 National Reimbursement Drug List (NRDL) negotiations
- Expected Timeline: Formal NRDL negotiations anticipated later this year
- Market Impact: NRDL inclusion would significantly improve patient access and drive volume adoption in China’s public healthcare system
- Competitive Positioning: As China’s first domestically developed IL-1β mAb for gout, firsekibart represents a strategic asset in the growing biologics market for inflammatory conditions
Strategic Implications
For Changchun GeneScience
- Portfolio expansion: Building on existing gout franchise with complementary indication
- Revenue diversification: Moving from acute treatment to chronic management paradigm
- Biologics leadership: Strengthening position in China’s domestic monoclonal antibody development landscape
Market Opportunity
- Gout prevalence: Estimated 40-60 million gout patients in China, with growing incidence due to dietary and lifestyle factors
- ULT adoption: Increasing use of urate-lowering therapies creates substantial prophylactic market opportunity
- Treatment gap: Limited options for flare prevention during ULT initiation represent significant unmet medical need
The expanded clinical development program positions firsekibart as a comprehensive gout management solution, potentially capturing both acute treatment and prophylactic market segments.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market access for firsekibart. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech